Skip to main content
SNSE
NASDAQ Life Sciences

CFO Invests Over $400K in Open Market Purchases, Signaling Strong Conviction

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$13.85
Mkt Cap
$18.586M
52W Low
--
52W High
--
52W Position
Off High
Rel. Volume
Market data snapshot near publication time

Summary

Faeth Therapeutics' CFO made a significant open market purchase of over $400,000, indicating strong insider conviction after recent corporate changes and a 'going concern' disclosure.


Key Events · Ownership and Investor Activity · SNSE

  • CFO Open Market Purchase

    Chief Financial Officer Brian C. Stephenson acquired 17,413 shares of common stock for a total of $405,921 through open market transactions on June 22-23, 2026. The purchase prices ranged from $20.23 to $25.91 per share.

  • Significant Insider Investment

    This purchase represents 2.184% of the company's market capitalization, indicating a high level of personal conviction from a key executive.

  • Post-Restructuring Confidence

    The investment follows recent major corporate events, including a $200 million private placement, an acquisition, and 'going concern' language in the Q1 2026 10-Q, suggesting the CFO sees value and stability post-restructuring.


Analysis · SNSE · Life Sciences

The Chief Financial Officer's substantial open market purchase of over $400,000 in company stock, representing more than 2% of the company's market capitalization, demonstrates significant confidence in the company's future. This investment follows a period of major corporate restructuring, a $200 million private placement, and an acquisition, making the insider's personal commitment particularly noteworthy amidst recent 'going concern' disclosures.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 51.2% of the 201 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.73%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SNSE was trading at $13.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.6M. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SNSE - Latest Insights

SNSE
Jun 26, 2026, 7:40 PM EDT
Filing Type: 4
Importance Score:
9
Price at Filing: $13.85
Real-time Price: $13.85 info
Change: $0 (0%) info
Market Cap: $18.586M info
SNSE
Jun 24, 2026, 6:55 PM EDT
Filing Type: 4
Importance Score:
9
Price at Filing: $13.85
Real-time Price: $13.85 info
Change: $0 (0%) info
Market Cap: $18.586M info
SNSE
Jun 18, 2026, 5:13 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $13.85
Real-time Price: $13.85 info
Change: $0 (0%) info
Market Cap: $18.586M info
SNSE
Jun 18, 2026, 4:01 PM EDT
Filing Type: S-3ASR
Importance Score:
9
Price at Filing: $13.85
Real-time Price: $13.85 info
Change: $0 (0%) info
Market Cap: $18.586M info
SNSE
Jun 16, 2026, 4:38 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $13.85
Real-time Price: $13.85 info
Change: $0 (0%) info
Market Cap: $18.586M info